INCREASING IMMUNE TOLERANCE IN VCAS WITH INNOVATIVE PRC-210 AND IDENTIFYING NEW CORRESPONDING PERIPHERAL BIOMARKER FOR ACUTE AND CHRONIC VCA REJECTION

Obvia Pharmaceuticals, Ltd.

Investigators